UBS AM
ACOR

UBS AM’s Acorda Therapeutics ACOR Stock Holding History

UBS AM’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-278
Closed -$95.8K – 2903
2019
Q3 		$95.8K Buy
278
+26
+10% +$14.1K ﹤0.01% 2668
2019
Q2 		$232K Buy
252
+13
+5% +$16K ﹤0.01% 2497
2019
Q1 		$381K Buy
239
+15
+7% +$27K ﹤0.01% 2216
2018
Q4 		$418K Hold
224
– – ﹤0.01% 2065
2018
Q3 		$528K Sell
224
-47
-17% -$145K ﹤0.01% 2068
2018
Q2 		$934K Buy
271
+57
+27% +$175K ﹤0.01% 1834
2018
Q1 		$607K Buy
214
+21
+11% +$62.9K ﹤0.01% 1950
2017
Q4 		$497K Buy
193
+17
+10% +$48.3K ﹤0.01% 1976
2017
Q3 		$498K Buy
+176
New +$464K ﹤0.01% 1948
2017
Q1 		– Sell
-1
Closed -$1K – 2500
2016
Q4 		$1K Sell
1
-188
-99% -$447K ﹤0.01% 2485
2016
Q3 		$474K Hold
189
– – ﹤0.01% 2011
2016
Q2 		$579K Sell
189
-815
-81% -$2.65M ﹤0.01% 1888
2016
Q1 		$3.19M Sell
1,004
-133
-12% -$552K ﹤0.01% 1171
2015
Q4 		$5.84M Sell
1,137
-15,492
-93% -$67.7M 0.01% 1017
2015
Q3 		$52.9M Sell
16,629
-14,463
-47% -$56.1M 0.06% 350
2015
Q2 		$124M Buy
31,092
+7,032
+29% +$27.2M 0.12% 193
2015
Q1 		$96.1M Sell
24,060
-2,381
-9% -$10.9M 0.09% 248
2014
Q4 		$130M Sell
26,441
-458
-2% -$1.97M 0.12% 188
2014
Q3 		$109M Buy
26,899
+2,253
+9% +$8.45M 0.11% 207
2014
Q2 		$99.7M Buy
24,646
+2,448
+11% +$9.98M 0.1% 240
2014
Q1 		$101M Sell
22,198
-3
-0% -$12.1K 0.11% 216
2013
Q4 		$77.8M Buy
22,201
+1,539
+7% +$6M 0.09% 250
2013
Q3 		$85M Buy
20,662
+125
+0.6% +$538K 0.11% 220
2013
Q2 		$81.3M Buy
+20,537
New +$84.6M 0.1% 226

Other funds holding ACOR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

UBS AM's ACOR Position: Q4 2019 in Review

UBS AM sold out of Acorda Therapeutics (ACOR) in Q4 2019, closing a stake of 278 shares — an estimated $95.8K sold.

UBS AM first reported a position in ACOR in Q2 2013 and held it in 24 quarters. The position peaked at $130M in Q4 2014. 121 funds tracked by Wall St. Rank hold ACOR as of Q4 2019.

  • UBS AM reported no remaining Acorda Therapeutics position as of Q4 2019 after selling out during the quarter.
  • UBS AM sold 278 Acorda Therapeutics shares in Q4 2019, an estimated $95.8K.
  • UBS AM first reported a position in Acorda Therapeutics in Q2 2013 and held it in 24 quarters.
  • UBS AM's Acorda Therapeutics position peaked at $130M in Q4 2014.
  • 121 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q4 2019.

Based on UBS AM's 13F filing for Q4 2019, filed 14 Feb 2020.